Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Return on Capital Employed (2018 - 2025)

Sutro Biopharma's Return on Capital Employed history spans 8 years, with the latest figure at 1.13% for Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 75.0% year-over-year to 1.13%; the TTM value through Sep 2025 reached 1.13%, down 75.0%, while the annual FY2024 figure was 0.8%, 54.0% down from the prior year.
  • Return on Capital Employed for Q3 2025 was 1.13% at Sutro Biopharma, down from 0.94% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.19% in Q2 2021 and bottomed at 1.13% in Q1 2025.
  • The 5-year median for Return on Capital Employed is 0.38% (2024), against an average of 0.48%.
  • The largest annual shift saw Return on Capital Employed increased 29bps in 2021 before it plummeted -84bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.31% in 2021, then dropped by -22bps to 0.38% in 2022, then surged by 35bps to 0.25% in 2023, then plummeted by -232bps to 0.83% in 2024, then crashed by -36bps to 1.13% in 2025.
  • Per Business Quant, the three most recent readings for STRO's Return on Capital Employed are 1.13% (Q3 2025), 0.94% (Q2 2025), and 1.13% (Q1 2025).